var data={"title":"Diphenhydramine (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diphenhydramine (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/393210?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diphenhydramine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Diphenhydramine (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=diphenhydramine-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Diphenhydramine (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082074\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aler-Dryl [OTC];</li>\n      <li>Allergy Relief Childrens [OTC];</li>\n      <li>Allergy Relief [OTC];</li>\n      <li>Altaryl [OTC] [DSC];</li>\n      <li>Anti-Hist Allergy [OTC];</li>\n      <li>Banophen [OTC];</li>\n      <li>Benadryl Allergy Childrens [OTC];</li>\n      <li>Benadryl Allergy [OTC];</li>\n      <li>Benadryl Dye-Free Allergy [OTC] [DSC];</li>\n      <li>Benadryl [OTC] [DSC];</li>\n      <li>Complete Allergy Medication [OTC];</li>\n      <li>Complete Allergy Relief [OTC];</li>\n      <li>Dicopanol FusePaq;</li>\n      <li>Dicopanol RapidPaq;</li>\n      <li>Diphen [OTC];</li>\n      <li>Diphenhist [OTC];</li>\n      <li>Genahist [OTC];</li>\n      <li>Geri-Dryl [OTC];</li>\n      <li>GoodSense Allergy Relief [OTC];</li>\n      <li>GoodSense Sleep Aid [OTC];</li>\n      <li>GoodSense SleepTime [OTC];</li>\n      <li>Naramin [OTC];</li>\n      <li>Nighttime Sleep Aid [OTC];</li>\n      <li>Nytol Maximum Strength [OTC];</li>\n      <li>Nytol [OTC];</li>\n      <li>Ormir [OTC];</li>\n      <li>PediaCare Childrens Allergy [OTC];</li>\n      <li>Pharbedryl;</li>\n      <li>Pharbedryl [OTC];</li>\n      <li>Q-Dryl [OTC] [DSC];</li>\n      <li>QlearQuil Nighttime Allergy [OTC] [DSC];</li>\n      <li>Quenalin [OTC] [DSC];</li>\n      <li>Scot-Tussin Allergy Relief [OTC];</li>\n      <li>Siladryl Allergy [OTC];</li>\n      <li>Silphen Cough [OTC] [DSC];</li>\n      <li>Simply Allergy [OTC] [DSC];</li>\n      <li>Simply Sleep [OTC];</li>\n      <li>Sleep Tabs [OTC];</li>\n      <li>Sominex Maximum Strength [OTC] [DSC];</li>\n      <li>Sominex [OTC] [DSC];</li>\n      <li>Tetra-Formula Nighttime Sleep [OTC];</li>\n      <li>Total Allergy Medicine [OTC];</li>\n      <li>Total Allergy [OTC];</li>\n      <li>Triaminic Cough/Runny Nose [OTC] [DSC];</li>\n      <li>ZzzQuil [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082075\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Allerdryl;</li>\n      <li>Allernix;</li>\n      <li>Benadryl;</li>\n      <li>Nytol;</li>\n      <li>Nytol Extra Strength;</li>\n      <li>PMS-Diphenhydramine;</li>\n      <li>Simply Sleep;</li>\n      <li>Sominex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10824348\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Drug-induced Dystonic Reactions</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Hypersensitivity Reactions</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihistamine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sedative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10824428\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=diphenhydramine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Diphenhydramine (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Oral solutions are available in two concentrations [ie, 12.5 mg/5 mL and 50 mg/30 mL (eg, ZzzQuil)]; precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as &quot;mg;&quot; the 50 mg/30 mL oral solution is indicated for the occasional treatment of insomnia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergies; hay fever:</b> Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: 5 mg/kg/day divided into 3-4 doses; maximum daily dose: 300 mg/day; age-related maximum daily doses may also be considered: &lt;6 years: 37.5 mg/day; 6-11 years: 150 mg/day; &ge;12 years: 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 2 to &lt;6 years: Limited data available: 6.25 mg every 4-6 hours; maximum daily dose: 37.5 mg/day (Kliegman, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to &lt;12 years: 12.5-25 mg every 4-6 hours; maximum daily dose: 150 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 25-50 mg every 4-6 hours; maximum daily dose: 300 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic reaction (severe)/anaphylaxis (adjunct to epinephrine):</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: IV, IM, Oral: 1.25 mg/kg/dose given every 6 hours; maximum daily dose: 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing:  IV, IM, Oral: 1-2 mg/kg/dose; maximum single dose: 50 mg/<b>dose</b> (Hegenbarth, 2008; Kliegman, 2011; Liberman, 2008; Lieberman, 2010; Simons, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinitis, sneezing due to common cold:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to &lt;12 years: 25 mg every 4-6 hours; maximum daily dose: 150 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 25-50 mg every 4-6 hours; maximum daily dose: 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dystonic reactions:</b> Infants, Children, and Adolescents: IV, IM: 1-2 mg/kg/dose; maximum single dose: 50 mg (Hegenbarth, 2008; Kliegman, 2011); may repeat in 20-30 minutes if necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Motion sickness:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis: Oral:  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: First dose should be administered 30 minutes before travel.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed dosing: 5 mg/kg/day divided into 3-4 doses; maximum daily dose: 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Fixed dosing: 12.5-25 mg 3-4 times daily  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: Children 2-12 years: Limited data available: 0.5-1 mg/kg/dose every 6 hours; maximum single dose: 25 mg. First dose should be administered 1 hour before travel (CDC, 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV, IM: 1.25 mg/kg/dose every 6 hours; maximum daily dose: 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed dosing: 5 mg/kg/day divided into 3-4 doses; maximum daily dose: 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Fixed dosing: 12.5-25 mg 3-4 times daily  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Insomnia; occasional:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2-12 years, weighing 10-50 kg: Limited data available: 1 mg/kg administered 30 minutes before bedtime; maximum single dose: 50 mg (Russo, 1976)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 50 mg administered 30 minutes before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pruritis (opioid-induced):</b> Limited data available: Infants, Children, and Adolescents: IM, IV, Oral: 0.5-1 mg/kg/dose every 6 hours; maximum daily dose: 100 mg/<b>day</b> (Kliegman, 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urticaria:</b>  Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: 5 mg/kg/day divided into 3-4 doses; maximum daily dose: 300 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing: 12.5-25 mg 3-4 times daily  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic reactions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 25-50 mg every 6-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 10-50 mg per dose; single doses up to 100 mg may be used if needed; not to exceed 400 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antitussive:</b> Oral: 25 mg every 4 hours; maximum: 150 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Motion sickness</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 25-50 mg every 6-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 10-50 mg per dose; single doses up to 100 mg may be used if needed; not to exceed 400 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Insomnia; occasional:</b> Oral: 50 mg at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dystonic reactions:</b> IM, IV: 50 mg in a single dose; may repeat in 20-30 minutes if necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082201\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allergy Relief: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), butylparaben, edetate calcium disodium, fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow), methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Banophen: 25 mg, 50 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl: 25 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl Allergy: 25 mg [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl Dye-Free Allergy: 25 mg [DSC] [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diphenhist: 25 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), butylparaben, fd&amp;c red #40, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diphenhist: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genahist: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Geri-Dryl: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Allergy Relief: 25 mg [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Sleep Aid: 50 mg [gluten free; contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense SleepTime: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ormir: 50 mg [contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pharbedryl: 25 mg, 50 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Q-Dryl: 25 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), butylparaben, fd&amp;c red #40, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZzzQuil: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Elixir, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Altaryl: 12.5 mg/5 mL (120 mL [DSC], 480 mL [DSC], 3840 mL [DSC]) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 12.5 mg/5 mL (5 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allergy Relief Childrens: 12.5 mg/5 mL (118 mL, 480 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Banophen: 12.5 mg/5 mL (118 mL) [alcohol free; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Banophen: 12.5 mg/5 mL (473 mL) [alcohol free, sugar free; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl Allergy Childrens: 12.5 mg/5 mL (5 mL [DSC], 118 mL, 236 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl Allergy Childrens: 12.5 mg/5 mL (236 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl Allergy Childrens: 12.5 mg/5 mL (118 mL) [alcohol free, dye free, sugar free; contains saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diphenhist: 12.5 mg/5 mL (118 mL, 473 mL) [alcohol free; contains fd&amp;c red #40, saccharin sodium, sodium benzoate; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Geri-Dryl: 12.5 mg/5 mL (473 mL) [alcohol free; contains fd&amp;c red #40, saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense SleepTime: 50 mg/30 mL (177 mL, 355 mL) [gluten free; contains alcohol, usp, brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, propylene glycol, saccharin sodium, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Naramin: 12.5 mg/5 mL (5 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PediaCare Childrens Allergy: 12.5 mg/5 mL (118 mL) [alcohol free; contains fd&amp;c red #40, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Q-Dryl: 12.5 mg/5 mL (118 mL [DSC], 237 mL [DSC], 473 mL [DSC]) [alcohol free; contains fd&amp;c red #40, saccharin sodium, sodium benzoate; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Scot-Tussin Allergy Relief: 12.5 mg/5 mL (118.3 mL, 240 mL, 480 mL, 3780 mL) [alcohol free, dye free, saccharin free, sodium free, sorbitol free, sugar free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Siladryl Allergy: 12.5 mg/5 mL (118 mL, 237 mL, 473 mL) [alcohol free, sugar free; contains fd&amp;c red #40, methylparaben, propylene glycol, propylparaben, saccharin sodium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Total Allergy Medicine: 12.5 mg/5 mL (118 mL) [alcohol free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZzzQuil: 50 mg/30 mL (177 mL, 354 mL) [contains alcohol, usp, brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, propylene glycol, saccharin sodium, sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZzzQuil: 50 mg/30 mL (354 mL) [contains alcohol, usp, brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, propylene glycol, saccharin sodium, sodium benzoate; vanilla cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ZzzQuil: 50 mg/30 mL (177 mL, 354 mL) [alcohol free; contains brilliant blue fcf (fd&amp;c blue #1), propylene glycol, saccharin sodium, sodium benzoate; mango berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (1 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Strip, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Triaminic Cough/Runny Nose: 12.5 mg (16 ea [DSC]) [contains alcohol, usp, brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dicopanol FusePaq: 5 mg/mL (150 mL) [contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dicopanol RapidPaq: 5 mg/mL (150 mL) [dye free, paraben free, sugar free; contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Altaryl: 12.5 mg/5 mL (120 mL [DSC], 480 mL [DSC], 3785 mL [DSC]) [alcohol free; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Quenalin: 12.5 mg/5 mL (120 mL [DSC]) [fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Silphen Cough: 12.5 mg/5 mL (118 mL [DSC], 237 mL [DSC], 473 mL [DSC]) [contains alcohol, usp, fd&amp;c red #40, menthol, methylparaben, propylene glycol, propylparaben; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aler-Dryl: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allergy Relief: 25 mg [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Hist Allergy: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Banophen: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl: 25 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl Allergy: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl Allergy: 25 mg [DSC] [contains edetate calcium disodium, fd&amp;c red #40, methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Complete Allergy Medication: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Complete Allergy Relief: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diphen: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diphenhist: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Geri-Dryl: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nighttime Sleep Aid: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nighttime Sleep Aid: 25 mg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nighttime Sleep Aid: 50 mg [DSC] [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nytol: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nytol Maximum Strength: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">QlearQuil Nighttime Allergy: 25 mg [DSC] [contains fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Simply Allergy: 25 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Simply Sleep: 25 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sleep Tabs: 25 mg [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sominex: 25 mg [DSC] [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sominex Maximum Strength: 50 mg [DSC] [contains fd&amp;c blue #1 aluminum lake, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tetra-Formula Nighttime Sleep: 50 mg [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Total Allergy: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl Allergy Childrens: 12.5 mg [DSC] [contains aspartame, fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benadryl Allergy Childrens: 12.5 mg [contains fd&amp;c blue #1 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082077\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25968298\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=diphenhydramine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Diphenhydramine (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dicopanol FusePaq is a compounding kit for the preparation of an oral suspension.  Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10824429\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May administer without regards to meals; when used to prevent motion sickness, first dose should be given 30 to 60 minutes prior to exposure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: For IV or IM administration only. Local necrosis may result with SubQ or intradermal use. For IV administration, may administer IVP undiluted at a rate &le;25 mg/minute or further diluted as an intermittent infusion over 10 to 15 minutes. <b>Note:</b> Seizures may be precipitated with too rapid IV administration in pediatric patients (Hegenbarth 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082128\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light and freezing. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:  Store at room temperature.  Protect capsules and tablets from moisture. Protect oral solution from freezing and light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10824349\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prescription products: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (Liquid: 12.5 mg per 5 mL): Treatment of allergic reactions caused by histamine release, adjunct to epinephrine in anaphylaxis after acute symptoms have been controlled, relief of other uncomplicated acute allergic conditions including urticaria and angioedema, treatment and prophylaxis of motion sickness, management of Parkinsonian \tsyndrome including drug-induced extrapyramidal symptoms (dystonic reactions) alone or in combination with centrally \tacting anticholinergic agents, treatment of allergic conjunctivitis, and dermatographism (FDA approved in ages &ge;28 days and adults); treatment of occasional insomnia (FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Parenteral: Treatment of allergic reactions caused by histamine release; adjunct to epinephrine in anaphylaxis after acute symptoms have been controlled; relief of other uncomplicated acute allergic conditions including urticaria and angioedema; treatment of motion sickness; management of Parkinsonian syndrome including drug-induced extrapyramidal symptoms (dystonic reactions) alone or in combination with centrally acting anticholinergic agents (All indications: FDA approved in ages &ge;28 days and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC products: Relief of symptoms of hay fever or other respiratory allergies [OTC products: Capsules, tablets, liquid (12.5 mg per 5 mL): FDA approved in ages &ge;6 years and adults]; relief of symptoms of common cold (OTC products: Capsules and tablets: FDA approved in ages &ge;6 years and adults); treatment of occasional insomnia [OTC products: Capsules, liquid (50 mg per 30 mL): FDA approved in ages &ge;12 years and adults]. <b>Note:</b> Approved uses for generic products may vary; consult labeling for specific information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082072\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">DiphenhydrAMINE may be confused with desipramine, dicyclomine, dimenhyDRINATE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Benadryl may be confused with benazepril, Bentyl, Benylin, Caladryl</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Diphenhydramine (oral), a first-generation antihistamine, is identified in the Beers Criteria  as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic. However, use of diphenhydramine <i>may be appropriate</i> in certain situations such as acute treatment of severe allergic reaction (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Benadryl brand name for diphenhydramine [U.S., Canada], but also the brand name for cetirizine [Great Britain, Phillipines] and acrivastine and pseudoephedrine [Great Britain]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Sominex brand name for diphenhydramine [U.S., Canada], but also the brand name for promethazine [Great Britain]; valerian [Chile]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082111\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest tightness, extrasystoles, hypotension, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Ataxia, chills, confusion, dizziness, drowsiness, euphoria, excitement, fatigue, headache, insomnia, irritability, nervousness, neuritis, paradoxical excitation, paresthesia, restlessness, sedation, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Menstrual disease (early menses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Anorexia, constipation, diarrhea, dry mucous membranes, epigastric distress, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Difficulty in micturition, urinary frequency, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, hemolytic anemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactic shock</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Labyrinthitis (acute), tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Constriction of the pharynx, nasal congestion, thickening of bronchial secretions, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082106\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Hypersensitivity to diphenhydramine, other structurally related antihistamines, or any component of the formulation; neonates or premature infants; breast-feeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications: Parenteral: Use as a local anesthetic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use in children &lt;6 years, to make a child sleep, or with any other diphenhydramine-containing products (including topical products)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082107\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Use with caution in patients with a history of asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia, bladder neck obstruction, and/or GU obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Antihistamines may cause excitation in young children. Toxicity (overdose) in pediatric patients may result in hallucinations, convulsions, or death; neonates and young children are highly sensitive to depressive effects of diphenhydramine; use is contraindicated in neonates and premature infants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alcohol: Some oral liquid products may contain alcohol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral liquid: Oral solutions are available in two concentrations (ie, 12.5 mg/5 mL and 50 mg/30 mL [eg, ZzzQuil]); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as &quot;mg&quot;; the 50 mg/30 mL oral solution is indicated for the occasional treatment of insomnia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parenteral: Subcutaneous or intradermal use has been associated with tissue necrosis; administer IV or IM only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar, 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Soy protein: Some preparations contain soy protein; avoid use in patients with soy protein or peanut allergies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): Do not use with other products containing diphenhydramine, even ones used on the skin. Oral products are not for OTC use in children &lt;6 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25856059\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in this age group. Serious adverse effects, including death, have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA notes that there are no approved OTC uses for these products in pediatric patients &lt;2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient. Toxicity (overdosage) in pediatric patients can result in hallucinations, convulsions, or death. Neonates and infants are highly sensitive to depressive effects of diphenhydramine; use is contraindicated in neonates (premature and term); use with extreme caution in infants and young children (AAP 2012; FDA 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082113\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2D6 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082114\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15970&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the sedative effect of Antihistamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082101\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082102\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Diphenhydramine crosses the placenta (Miller 2000; Parkin 1974). In general, the use of first generation antihistamines immediately before parturition may cause respiratory depression in the newborn (Zuberbier 2014). Diphenhydramine may be used for the treatment of allergic conditions in pregnant women when a first generation antihistamine is indicated (Babalola 2013; Murase 2014; Zuberbier 2014). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy (Ambros-Rudolph 2011; Kremer 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082131\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract; anticholinergic and sedative effects are also seen</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082134\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Histamine-induced wheal suppression: &le;10 hours (Simons, 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Histamine-induced flare suppression: &le;12 hours (Simons, 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Children: 22 L/kg (range: 15 to 28 L/kg); Adults: 17 L/kg (range: 13 to 20 L/kg); Elderly: 14 L/kg (range: 7 to 20 L/kg) (Blyden, 1986; Simons, 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 98.5% (Vozeh, 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic n-demethylation via CYP2D6; minor demethylation via  CYP1A2, 2C9 and 2C19; smaller degrees in pulmonary and renal systems; significant first-pass effect (Akutsu, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 42% to 62% (Paton, 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children: 5 hours (range: 4 to 7 hours); Adults: 9 hours (range: 7 to 12 hours); Elderly: 13.5 hours (range: 9 to 18 hours) (Blyden, 1986; Simons, 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~2 hours (Blyden, 1986; Simons, 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as metabolites and unchanged drug) (Albert, 1975; Maurer, 1988)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8082205\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Banophen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $2.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $2.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (DiphenhydrAMINE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $4.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $8.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Benadryl Allergy Childrens Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (20): $5.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Elixir</b> (DiphenhydrAMINE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg/5 mL (10 mL): $1.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Banophen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg/5 mL (118 mL): $2.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Benadryl Allergy Childrens Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg/5 mL (118 mL): $5.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Naramin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg/5 mL (5 mL): $1.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Scot-Tussin Allergy Relief Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg/5 mL (240 mL): $6.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Total Allergy Medicine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg/5 mL (118 mL): $4.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (ZzzQuil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/30 mL (354 mL): $7.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DiphenhydrAMINE HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (1 mL): $0.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Dicopanol FusePaq Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (150 mL): $495.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Dicopanol RapidPaq Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (150 mL): $518.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Banophen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (24): $1.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Benadryl Allergy Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (48): $5.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (DiphenhydrAMINE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $1.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Nytol Maximum Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (8): $3.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Nytol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (72): $8.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Simply Sleep Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (24): $3.94</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962013\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aliserin (IT);</li>\n      <li>Allermin (JP);</li>\n      <li>Amydramine (KW);</li>\n      <li>Amydramine-II (AE, LB, QA);</li>\n      <li>Amydramkine-II (SA);</li>\n      <li>Azaron (BE);</li>\n      <li>Beanamine (SG);</li>\n      <li>Belarmin (TR);</li>\n      <li>Bena (HK);</li>\n      <li>Benadrex (PH);</li>\n      <li>Benadryl (AR, CO, ES, GR, IN, MY, PH, PK, TH, VE, VN);</li>\n      <li>Benadryl A (UY);</li>\n      <li>Benadryl Allergy (PE);</li>\n      <li>Benadryl for the Family Original (AU);</li>\n      <li>Benamine (TW);</li>\n      <li>Bendol (HK);</li>\n      <li>Benocten (AE, CH);</li>\n      <li>Benylan (DK);</li>\n      <li>Bexil (PH);</li>\n      <li>Broncho D (IL);</li>\n      <li>Butix (FR);</li>\n      <li>Calm U (NZ);</li>\n      <li>Calmaben (AT, BG);</li>\n      <li>Cerylana (VE);</li>\n      <li>Daedalon (HU);</li>\n      <li>Danzamin (KR);</li>\n      <li>Desentol (SE);</li>\n      <li>DiBendryl (TH);</li>\n      <li>Dibrondrin (AT);</li>\n      <li>Didra (BD);</li>\n      <li>Didryl (BD);</li>\n      <li>Difenidrin (BR);</li>\n      <li>Dormital (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Dormutil (DE);</li>\n      <li>Dramylin (QA);</li>\n      <li>Exylin (KW, QA);</li>\n      <li>Fenilar (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Histergan (BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Hydramine (TW);</li>\n      <li>Hydrazol (PH);</li>\n      <li>Hyphen (PH);</li>\n      <li>Menna (TW);</li>\n      <li>Nardyl (DE);</li>\n      <li>Nytol (IL);</li>\n      <li>Otede (ID);</li>\n      <li>Pediphen (BD);</li>\n      <li>Phenadryl (BD);</li>\n      <li>Phenycof (LK);</li>\n      <li>Psilo Balsam (CZ, RU);</li>\n      <li>R Calm (BE);</li>\n      <li>Rabaphen (PH);</li>\n      <li>Recodryl (ID);</li>\n      <li>Resmin (JP);</li>\n      <li>Rivedramine (JO);</li>\n      <li>Sleepeze-PM (ZA);</li>\n      <li>Snuzaid (AU);</li>\n      <li>Somol (CL);</li>\n      <li>Soniphen (PH);</li>\n      <li>Sonodor (ES);</li>\n      <li>Unisom Sleepgels (AU, NZ);</li>\n      <li>Valdres (ID);</li>\n      <li>Vena (JP);</li>\n      <li>Venapas Oint (TW);</li>\n      <li>Venasmin (JP);</li>\n      <li>Vertirosan (AT);</li>\n      <li>Vivinox (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ambros-Rudolph CM, &quot;Dermatoses of Pregnancy - Clues to Diagnosis, Fetal Risk and Therapy,&quot; <i>Ann Dermatol</i>, 2011, 23(3):265-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/21909194/pubmed\" target=\"_blank\" id=\"21909194\">21909194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). Five things physicians and patients should question. April 4, 2012. Available at http://www.choosingwisely.org/choosing-wisely-five-things-physicians-and-patients-should-question-press-release-april-4-2012/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Babalola O, Strober BE. Treatment of atopic dermatitis in pregnancy. <i>Dermatol Ther</i>. 2013;26(4):293-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/23914886/pubmed\" target=\"_blank\" id=\"23914886\">23914886</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). <i>CDC Health Information for International Travel 2014</i>. New York: Oxford University Press; 2014; Chapter 2. <a href=\"http://wwwnc.cdc.gov/travel/page/yellowbook-home-2014\" target=\"_blank\">http://wwwnc.cdc.gov/travel/page/yellowbook-home-2014</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA). OTC cough and cold products: not for infants and children under 2 years of age. January 17, 2008. Available at <a href=\"http://www.fda.gov/forconsumers/consumerupdates/ucm048682.htm\" target=\"_blank\">http://www.fda.gov/forconsumers/consumerupdates/ucm048682.htm</a>. Last accessed January 29, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008; 121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, et al, &quot;Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication,&quot; <i>Am J Obstet Gynecol</i>, 1993, 168(5):1393-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knowles JA, &quot;Excretion of Drugs in Milk - A Review,&quot; <i>J Pediatr</i>, 1965, 66:1068-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/14288461/pubmed\" target=\"_blank\" id=\"14288461\">14288461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kremer AE, Bolier R, van Dijk R, et al. Advances in pathogenesis and management of pruritus in cholestasis. <i>Dig Dis</i>. 2014;32(5):637-645.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/25034299/pubmed\" target=\"_blank\" id=\"25034299\">25034299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liberman DB, Teach SJ. Management of anaphylaxis in children. <i>Pediatr Emerg Care</i>. 2008;24:861-869.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/19092569/pubmed\" target=\"_blank\" id=\"19092569\">19092569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. <i>J Allergy Clin Immunol</i>. 2010;126(3):477-480.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/20692689/pubmed\" target=\"_blank\" id=\"20692689\">20692689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messinis IE, Souvatzoglou A, Fais N, et al, &quot;Histamine H1 Receptor Participation in the Control of Prolactin Secretion in Postpartum,&quot; <i>J Endocrinol Invest</i>, 1985, 8(2):143-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/3928731/pubmed\" target=\"_blank\" id=\"3928731\">3928731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller AA, &quot;Diphenhydramine Toxicity in a Newborn: A Case Report,&quot; <i>J Perinatol</i>, 2000, 20(6):390-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/11002881/pubmed\" target=\"_blank\" id=\"11002881\">11002881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):401.e1-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parkin DE, &quot;Probable Benadryl Withdrawal Manifestations in a Newborn Infant,&quot; <i>J Pediatr</i>, 1974, 85(4):580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/4443870/pubmed\" target=\"_blank\" id=\"4443870\">4443870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell RJ, Leech SC, Till S, et al; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. <i>Clin Exp Allergy</i>. 2015;45(3):547-565.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/25711134/pubmed\" target=\"_blank\" id=\"25711134\">25711134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rindi V. La eliminazione degli antistaminici di sintesi con il latte e l'azione latto-goga de questi. <i>Riv Ital Ginecol.</i> 1951;34:147-57. As reported by LACTMED:<a href=\"https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+96\" target=\"_blank\"> http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+96</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russo RM, Guraraj VJ, Allen JE. The effectiveness of diphenhydramine HCl in pediatric sleep disorders. <i>J Clin Pharmacol</i>. 1976;16: 284-288.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE, Ardusso LR, Bilo MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis.<i> World Allergy Organ J</i>. 2011;4:13-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/23268454/pubmed\" target=\"_blank\" id=\"23268454\">23268454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. <i>Allergy</i>. 2014;69(7):868-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/24785199/pubmed\" target=\"_blank\" id=\"24785199\">24785199</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15970 Version 251.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8082074\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8082075\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10824348\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10824428\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8082201\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8082077\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25968298\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10824429\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8082128\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10824349\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8082072\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8082111\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8082106\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8082107\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25856059\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8082113\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8082114\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8082101\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8082102\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8082131\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8082134\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8082205\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962013\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15970|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diphenhydramine-systemic-drug-information\" class=\"drug drug_general\">Diphenhydramine (systemic): Drug information</a></li><li><a href=\"topic.htm?path=diphenhydramine-systemic-patient-drug-information\" class=\"drug drug_patient\">Diphenhydramine (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}